Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.
BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.
The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.
In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.
BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.
For more information, please visit www.biocryst.com or follow them on LinkedIn.
BioCryst Pharmaceuticals (BCRX) announced the granting of stock options and restricted stock units (RSUs) to 12 newly-hired employees. The total grants include options for 110,400 shares and RSUs for 51,300 shares, effective February 28, 2023. The options have an exercise price of $8.85, aligning with the company's common stock closing price on the grant date. Vesting occurs in four equal annual installments, contingent upon the employees' continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of BioCryst's Inducement Equity Incentive Plan.
BioCryst Pharmaceuticals announced significant findings from the APeX-S and APeX-2 clinical trials for ORLADEYO (berotralstat), an oral medication for hereditary angioedema (HAE). The final results showed a median attack rate of 0.0 attacks per month in 20 of 24 months. This treatment is well-tolerated, with no new safety signals, and demonstrates sustained reductions in attacks and improved quality of life among patients. These findings were presented at the 2023 AAAAI annual meeting. Real-world data further supports the effectiveness of ORLADEYO, highlighting the ongoing need for accessible treatment options.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in two upcoming healthcare conferences. The company will present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023, at 12:50 p.m. ET, and at the Barclays 2023 Global Healthcare Conference in Miami, FL, on March 14, 2023, at 9:30 a.m. ET. Investors can access live webcasts and replays via the Investors & Media section of BioCryst's website. The company focuses on developing innovative oral medicines for rare diseases with high unmet medical needs.
BioCryst Pharmaceuticals reported Q4 2022 net revenue of $70.7 million, with a full-year total of $251.6 million, reflecting a 72% year-over-year increase. The company projects 2023 revenue for ORLADEYO to reach no less than $320 million, anticipating peak sales of $1 billion. Financial results revealed a net loss of $71.5 million in Q4, up from $17.8 million a year prior. Total cash and investments as of December 31, 2022, stood at $443.9 million. R&D and SG&A expenses increased, attributed to higher investments for ORLADEYO's launch and ongoing programs. The company is focused on expanding its market reach with robust demand for ORLADEYO, now available in 15 countries.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announces it will report Q4 2022 financial results on February 21, 2023. The management will host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update. Investors can access the live call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live webcast and replay will be available on the company’s website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases with significant unmet medical needs, including products like ORLADEYO® and RAPIVAB®.
BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to 20 newly-hired employees as part of their incentive compensation plan. A total of 287,200 stock options and 101,700 RSUs will vest annually over four years, with a set exercise price of $10.55 per share, equating to the stock's closing price on the grant date of January 31, 2023. These grants comply with Nasdaq regulations. BioCryst focuses on developing novel medications for rare diseases, including ORLADEYO and RAPIVAB, both approved in various markets. For further details, visit their website.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its presentation of four abstracts on ORLADEYO (berotralstat), aimed at preventing hereditary angioedema (HAE) attacks, during the 2023 AAAAI annual meeting in San Antonio, Texas, from February 24-27. Highlights include new analyses from the long-term clinical program and real-world evidence indicating significant reductions in attack rates and improvements in the quality of life for patients. The abstracts will be presented on February 26 and are accessible in The Journal of Allergy and Clinical Immunology. ORLADEYO is the first oral therapy specifically designed for HAE prophylaxis.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has initiated the pivotal APeX-P trial, enrolling its first pediatric patient for the oral therapy ORLADEYO® (berotralstat) aimed at treating hereditary angioedema (HAE) in children aged 2 to <12 years. The trial will assess the pharmacokinetics and safety of ORLADEYO, following a 12-week standard-of-care period, leading into an open-label phase of 48 weeks and potentially extending to 144 weeks. The information gathered will support a supplemental New Drug Application (sNDA) for expanding ORLADEYO's use in pediatric patients. ORLADEYO is the first oral preventive therapy approved for HAE attacks in patients aged 12 years and older.
BioCryst Pharmaceuticals (BCRX) announced a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe (CEE). This partnership aims to make this oral prophylactic treatment for hereditary angioedema accessible to patients in 15 CEE markets. BioCryst is focused on addressing significant unmet needs in rare diseases, and Swixx brings extensive expertise in this area. The agreement highlights the commercialization efforts for a therapy that is the first oral treatment specifically designed to prevent HAE attacks in adults and children aged 12 and older.
BioCryst Pharmaceuticals (BCRX) reported preliminary ORLADEYO net revenue of $251.6 million for 2022, reflecting a 105% year-over-year increase. The fourth quarter generated $70.7 million in net revenue, a 53% increase from the previous year. Looking ahead, the company projects 2023 revenue to reach at least $320 million and anticipates peak ORLADEYO sales of $1 billion. Company executives noted strong market performance despite slight revenue lag due to seasonal factors.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
What is BioCryst Pharmaceuticals' main product?
Where is BioCryst Pharmaceuticals headquartered?
What therapeutic areas does BioCryst Pharmaceuticals focus on?
What recent achievements has BioCryst Pharmaceuticals reported?
How does ORLADEYO® work?
What is the pipeline of BioCryst Pharmaceuticals?
Who are BioCryst Pharmaceuticals' partners?
What is the company's approach to drug development?
What are some of the challenges BioCryst Pharmaceuticals addresses?
How can I stay updated on BioCryst Pharmaceuticals' latest news?
